Category - Developments

Developments

Lexicon signs exclusive licencing agreement with Viatris for sotagliflozin outside U.S. and Europe

Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced that Viatris (NASDAQ:VTRS) obtained an exclusive license from Lexicon to commercialize sotagliflozin across all indications outside the U.S. and Europe, in exchange...

October 17, 2024

Developments

Celularity expands portfolio acquiring Rebound from Sequence

Celularity (NASDAQ:CELU) has announced its acquisition of Rebound from Sequence LifeScience, expanding its commercial portfolio of placental-derived advanced biomaterial products. Rebound is a full thickness placental...

October 17, 2024

Developments

Corbus reports enrollment completion of dose escalation stage of Phase 1 trial

Corbus Pharmaceuticals (NASDAQ:CRBP) has announced the completion of enrollment for the dose-escalation portion of its bridging Phase 1 clinical trial of CRB-701 (SYS6002) in patients with advanced solid tumors...

October 16, 2024

Developments

EC grants orphan medicinal product designation of Theriva’s VCN-01 for retinoblastoma

Theriva Biologics (NYSE American:TOVX) has announced that the European Commission (EC) has adopted the European Medicines Agency’s (EMA) recommendation to grant orphan medicinal product designation to its lead...

October 16, 2024

Developments

Ripple and Glaukos ink evaluation and licensing agreements

Closely-held Ripple Therapeutics has announced evaluation and licensing agreements with Glaukos Corporation (NYSE:GKOS), enabling Glaukos to leverage Ripple’s proprietary technology platform to create sustained release...

October 15, 2024

Developments

Aurinia presents new real-world data reinforcing LUPKYNIS in LN at ASN Kidney Week 2024

Aurinia Pharmaceuticals (NASDAQ:AUPH) has announced plans to present new data reinforcing the clinical significance of LUPKYNIS in the treatment of lupus nephritis (LN) at the American Society of Nephrology (ASN) Kidney...

October 11, 2024

Developments

Turnstone restructures to focus resources on advancing Phase 1 study

Turnstone Biologics (NASDAQ:TSBX) has announced restructuring initiatives that include the strategic prioritization of its pipeline, a 60% workforce reduction, and changes to its leadership team, aimed at focusing...

October 11, 2024

Developments

Health Canada clears Palisade to commence Phase 1 study of PALI-2108 in UC

Palisade Bio (NASDAQ:PALI) has announced that it has received a No Objection Letter from Health Canada for its Phase 1 clinical trial of PALI-2108 for the treatment of ulcerative colitis (UC). The orally-administered...

October 10, 2024

Developments

Clearmind receives IRB approval for trial of CMND-100 for AUD at second clinical site

Clearmind Medicine (NASDAQ:CMND) has announced that it has received Institutional Review Board (IRB) approval from one of its U.S. clinical sites for part A of its Phase I/IIa clinical trial of CMND-100 for the...

October 10, 2024

Developments

SI-BONE reports first in-patient procedures with TNT implant system for pelvic fractures

SI-BONE (NASDAQ:SIBN) has announced the first in-patient procedures using its iFuse TORQ TNT Implant System (TNT), designed to address anatomic and biomedical challenges of pelvic fragility fractures as opposed to...

October 10, 2024

Category - Developments

Subscribe